These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 31363868)
21. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation. Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568 [TBL] [Abstract][Full Text] [Related]
22. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders. Yu J; Chan HK; Gengenbach T; Denman JA Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664 [TBL] [Abstract][Full Text] [Related]
23. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations. Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729 [TBL] [Abstract][Full Text] [Related]
24. Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres. Kaialy W; Hussain T; Alhalaweh A; Nokhodchi A Pharm Res; 2014 Jan; 31(1):60-76. PubMed ID: 23918220 [TBL] [Abstract][Full Text] [Related]
25. [Effect of separation characteristics between salbutamol sulfate (SS) particles and model carrier excipients on dry powder for inhalation]. Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Danjo K Yakugaku Zasshi; 1999 Oct; 119(10):752-62. PubMed ID: 10518459 [TBL] [Abstract][Full Text] [Related]
26. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development. Le VN; Robins E; Flament MP Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906 [TBL] [Abstract][Full Text] [Related]
27. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246 [TBL] [Abstract][Full Text] [Related]
28. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. Muddle J; Murnane D; Parisini I; Brown M; Page C; Forbes B J Pharm Sci; 2015 Nov; 104(11):3861-3869. PubMed ID: 26220184 [TBL] [Abstract][Full Text] [Related]
29. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961 [TBL] [Abstract][Full Text] [Related]
30. Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. Ooi J; Traini D; Hoe S; Wong W; Young PM Int J Pharm; 2011 Jul; 413(1-2):1-9. PubMed ID: 21501674 [TBL] [Abstract][Full Text] [Related]
31. Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer. Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J Pharm Res; 2017 Jan; 34(1):25-35. PubMed ID: 27604893 [TBL] [Abstract][Full Text] [Related]
32. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations. Kinnunen H; Hebbink G; Peters H; Shur J; Price R AAPS PharmSciTech; 2014 Aug; 15(4):898-909. PubMed ID: 24756910 [TBL] [Abstract][Full Text] [Related]
33. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties. Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834 [TBL] [Abstract][Full Text] [Related]
34. Dry Powder Inhalers Based on Chitosan-Mannitol Binary Carriers: Effect of the Powder Properties on the Aerosolization Performance. Zhao Z; Wang G; Huang Z; Huang Y; Chen H; Pan X; Zhang X AAPS PharmSciTech; 2022 Jun; 23(5):164. PubMed ID: 35697949 [TBL] [Abstract][Full Text] [Related]
35. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Momin MAM; Sinha S; Tucker IG; Das SC Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129 [TBL] [Abstract][Full Text] [Related]
36. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride. Karimi K; Katona G; Csóka I; Ambrus R J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047 [TBL] [Abstract][Full Text] [Related]
38. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. Jetmalani K; Young PM; Smith T; Stewart P; Traini D Drug Dev Ind Pharm; 2012 Dec; 38(12):1504-11. PubMed ID: 22335558 [TBL] [Abstract][Full Text] [Related]
39. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance. Cordts E; Steckel H Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789 [TBL] [Abstract][Full Text] [Related]
40. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance. Shalash AO; Khalafallah NM; Molokhia AM; Elsayed MMA AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]